 - Radiographically documented disease progression per modified Response Evaluation Criteria in Solid Tumors RECIST during or following treatment with fluoropyrimidine, irinotecan, andor oxaliplatin chemotherapy for Metastatic Colorectal Cancer. Progressive disease must be documented during or 6 months after the last dose of the most recent chemotherapy regimen prior to enrollment. 